Systematic review of genetic variants associated with cognitive impairment and depressive symptoms in Parkinson’s disease by D’Souza, Tyrra & Rajkumar, Anto P.
For Peer Review
Systematic review of genetic variants associated with 
cognitive impairment and depressive symptoms in 
Parkinson’s disease
Journal: Acta Neuropsychiatrica
Manuscript ID ACN-18-1597.R2
Manuscript Type: Review Article
Date Submitted by the 
Author: 11-Jun-2019
Complete List of Authors: D’Souza, Tyrra; Institute of Psychiatry, Psychology and Neuroscience, 
King's College London, Old age Psychiatry
Rajkumar, Anto P.; Institute of Psychiatry, Psychology and Neuroscience, 
King's College London, Old age Psychiatry; South London and Maudsley 
NHS Foundation Trust,  
Keywords: Cognition, Depression, Parkinson’s Disease, Systematic Review, Genetics
 
For Peer Review
6
6
in regards to the genetic associations of depression in the context of PD. Serotonin and 
dopamine are the two important neurotransmitters that are involved in the pathophysiology of 
depression. Their levels in synaptic clefts are regulated by neurotransmitter transporters, and 
it is the genetic variations of these transporters that are hypothesised as potential risk factors 
for depression in PD. Where the serotonin transporter gene (SLC6A4) has been extensively 
studied as a genetic risk factor for depression in people without PD (19), the dopamine 
transporter gene (SLC6A3) has been examined as a potential candidate gene for depression in 
PD (20). Additionally, variants in the parkin gene (PARK2) have also been shown to 
contribute to a heightened risk of both depression and anxiety in people with PD, especially 
to those with early onset PD (21). 
There are currently no systematic reviews that comprehensively summarise the 
relevant literature regarding the effects of genetic variants on non-motor symptoms in PD. 
This systematic review will be the first to provide a cohesive summary of all genetic 
association studies that have investigated the genetic factors associated with cognitive 
impairment and depression in people with PD. This review aims to enhance the 
understanding of the neurobiology underlying cognitive impairment and depression in people 
with PD.
Materials and Methods 
Study design: The protocol of this systematic review has been registered (PROSPERO 
protocol registration number: CRD42017067431), and is available online 
(http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017067431).
Inclusion Criteria: All articles studying human participants with a clinical diagnosis of 
Parkinson’s disease, irrespective of their age, and gender, were considered. Animal studies 
and invitro studies were excluded. Studies that investigated common and rare genetic 
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variations as well as cognitive impairment and/or depressive symptoms as outcome were 
included. Therefore, genetic association studies that did not include either of these as 
outcome variables were excluded. All relevant cohort studies, case controls, and case series 
were included. Studies were not excluded because of their controls or the lack of them.
Search strategy: A systematic search was carried out in January 2019 using the following 
five databases: PubMed (1996-Present), PsycINFO (1806-present), CINAHL (1981-present), 
EMBASE (1974-present) and OpenGrey. The search strategy was comprised of both 
‘Population’ AND ‘Exposure’ AND ‘Outcome’ terms. These terms were searched for in the 
titles, abstracts, and full texts. ‘Parkinson*’ was the population search term. The exposure 
search terms that were included: ‘Gene*’, OR ‘LRRK2’, OR ‘GBA’, OR ‘SNCA’. The 
outcome search terms that were used included: (‘Cognition’ OR ‘Cognitive’ OR ‘Memory’) 
OR (‘Depression’ OR ‘Depressive’). Articles that were not published in English were not 
included. 
Study selection: All articles obtained following the search of key terms were screened for 
their eligibility. The duplicates were removed using Mendeley Desktop 1.17.1 (Mendeley 
Ltd., London, UK). Articles were initially screened by their titles. The abstracts of remaining 
articles were then screened for relevance and were evaluated for their eligibility. Articles that 
did not have cognition or depression as an outcome variable and/or did not include PD 
service users as participants were deemed ineligible. Full texts of the remaining pertinent 
articles were then retrieved and assessed. All eligible articles were included in this systematic 
review. 
Quality assessment: The risk of bias and quality assessment of all eligible studies were 
carried out using the ‘Q-Genie’, a quality assessment tool for genetic association studies (22). 
The Q-Genie assesses the following 11 dimensions, (i) the rationale for study, (ii) selection 
and definition of outcome, (iii) selection and comparability of comparison groups, (iv) 
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technical classification of the genetic variant(s), (v) non-technical classification of the genetic 
variant(s), (vi) other sources of bias, (vii) sample size and power, (viii) a priori planning of 
statistical analyses, (ix) statistical methods and control for confounding, (x) tests of 
assumptions and inferences for the genetic analyses, and (xi) appropriate interpretation of the 
study results. Each dimension is scored on a scale from one (poor) to seven (excellent). For 
studies with control group, Q-Genie total scores ≤35 indicate poor quality, total scores more 
than 45 indicate good quality, and total scores between 36 and 45 indicate moderate quality. 
Total scores of ≤35 for studies with control groups and ≤32 for studies without control groups 
are rated having poor quality. Scores ranging between >35 and ≤45 for studies with control 
groups and >32 ≤40 without are rated having moderate quality, and those with scores >45 for 
with control groups and >42 for without are deemed good quality. The reliability and validity 
of the Q-Genie tool has already been demonstrated (23).
Data extraction: The data extracted from eligible studies were (i) Participants: The size of 
the cohort and their average age and standard deviation at the time of the study. Similarly, the 
corresponding Unified Parkinson’s Disease Rating Scale (UPDRS) (24) scores for each  
subgroup were extracted for indicating the severity of PD. (ii) Exposure: Gene names and the 
investigated single-nucleotide variants were extracted with their ‘rs’ number, if stated. When 
the included studies have not reported the ‘rs’ numbers, we searched the dbSNP database 
(https://www.ncbi.nlm.nih.gov/snp) with the reported names of the variants.  When our 
search could not establish an unique dbSNP identifier, we have reported the variant name as 
it was reported by the original study authors. (iii) Outcome: The outcome was classified as 
either ‘cognition’ or ‘depression’ to signify what was being measured. The measurement tool 
or test used to measure either outcome was recorded, for example ‘Mini-mental State 
Examination’ (MMSE) (25) or ‘Beck Depression Inventory’ (26). We obtained mean 
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differences between groups with statistical significance, as well as effect sizes and confidence 
intervals, if reported. Duration of follow-up was also obtained, if applicable.
Data synthesis and analyses: The data were firstly classified under the exposure variable 
(genes), and then classified under the outcome variables (cognition or depression). If three or 
more studies have investigated the association between a specific genetic variant and 
cognitive impairment or depression in PD, we combined the reported mean differences or 
effect sizes using fixed effect meta-analyses. Their degree of heterogeneity was assessed 
using Cochrane’s Q statistics and Higgin’s I2. We conducted the meta-analyses using the 
STATA 15.1 software (StataCorp LLC, TX, USA) and its “metan” command.
Results 
Included studies:  Figure-1 presents the Preferred Reporting Items for Systematic Review 
and Meta-Analyses (PRISMA) flow chart that exhibits the process of identifying all eligible 
studies.  Initial screening of the databases resulted in 2353 titles. 1647 were found in a joint 
search on PsychINFO and EMBASE, 685 on PubMed, five on CINAHL and 16 on 
OpenGrey. 43 articles were eligible to be included in this systematic review. Among them, 24 
measured cognition as an outcome variable, 13 measured depression as an outcome variable, 
and six measured both. LRRK2 and GBA were the most commonly investigated genes. 
Fourteen studies investigated PD service users, who are carriers of one of the GBA variants 
(rs76763715, rs75548401, rs421016, rs387906315 and rs80356773). Fourteen studies studied 
PD service users, who are carriers of LRRK2 variants (rs34637584, rs33939927, rs11564148 
and rs34778348). Other genes that have been investigated included SNCA (27), APOE, 
BDNF (rs6265), SLC6A4, COMT (Val158Met) and MAPT. Only 26 (60.5%) included studies 
have had sample sizes above 100. We present the quality assessment scores of the included 
studies in the supplementary information table-1. Their Q-Genie (22) total scores ranged 
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from 27 (28) to 55 (29) with main areas of concern being the technical and non-technical 
classification of the genetic exposure variables. 
LRRK2: Table-1 summarises the findings of the studies that investigated the effects of 
LRRK2 variants on cognition in people with PD. Four of these studies have reported that 
carriers of minor allele of rs34637584 exhibited significantly less cognitive impairment, 
while comparing with PD non-carriers (14,15,30,31). We conducted a meta-analysis of 
studies investigating this specific variant using different outcome measures and calculated 
their standardised mean difference (SMD=0.21; 95%CI 0.04-0.38) (Figure-2) 
(Supplementary figure-1). The meta-analysis confirmed that people with PD, who carried the 
minor allele of rs34637584, had significantly less cognitive impairment than non-carriers 
(z=2.43; p=0.015). However, studies investigating the effects of other LRRK2 variants, such 
as rs33939927, rs11564148, and rs33949390, did not report statistically significant difference 
on cognition between the carriers and non-carriers (28,32-37). Most of these studies were 
cross-sectional. They had relatively small sample sizes, and they have not reported power 
analyses (34).  Moreover, three studies have investigated the associations between LRRK2 
variants and depressive symptoms in PD. Two of them have reported that depression was 
significantly more prevalent among the rs34637584 minor allele carriers with PD than the 
non-carriers (33,38). However, another study investigating the association between LRRK2 
variants and depressive symptoms in PD using the Hospital Anxiety and Depression Scale 
did not replicate this finding (p=0.54) (39). 
GBA: Table-2 provides a summary of findings of the studies that investigated the effects of 
GBA variants on cognition in people with PD. Several studies have reported that minor allele 
carriers of various GBA variants had significantly worse cognitive function than the non-
carriers (12,31,40-45). Alcalay et al (12) found that minor allele carriers of GBA variants 
rs76763715 and rs36806 obtained significantly less MMSE scores than the non-carriers. 
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Moreover, a longitudinal study (41) investigating the effects of GBA variants including 
rs2230288 reported that significantly more carriers developed MCI or PDD, compared to 
non-carriers (OR=4.65; 95%CI 1.72-7.58; p=0.002). Malec-Litwinowicz et al (42) followed 
up only five people with PD and GBA variants, and found that minor allele carriers of 
rs76763715 developed significantly more cognitive impairment than non-carriers over time. 
GBA variant rs2230288 has been reported to be associated with significantly worse 
visuospatial abilities (45). However, there are studies that have reported that minor allele 
carriers of GBA variants rs76763715 and rs421016 did not differ significantly from non-
carriers on their cognition (32,46). One of them was a longitudinal study including three 
years of follow-up, but it included only 13 people with GBA variants (46). We conducted 
meta-analyses of the studies investigating the effects of GBA rs76763715 (Figure-3A) and 
rs421016 (Figure-3B) variants on cognition in people with PD (Supplementary figure-1). Our 
meta-analyses confirmed that both rs76763715 (z=3.54; p<0.001) and rs421016 (z=3.45; 
p=0.001) variants were significantly associated with more cognitive impairment in people 
with PD. 
Table-3 summarises the findings of five studies that investigated the associations 
between GBA variants and depressive symptoms in people with PD. Four studies that 
investigated GBA variant rs421016 (31,46-48), and two studies that investigated GBA variant 
rs76763715 (46,47) have consistently reported significantly more depressive symptoms in 
people with PD carrying minor alleles of these variants. GBA variants rs387906315 and 
rs80356773 have also been associated with significantly higher prevalence of depression 
among people with PD (47). However, a small longitudinal study following only 13 people 
with PD and GBA variants for three years has reported that mood symptoms did not differ 
significantly between the carriers and non-carriers during their follow-up (46). This study did 
not report relevant power analysis, and it did not consider the effects of potential confounders 
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such as age and gender during their analyses (46). Another small longitudinal study 
investigating a heterogeneous PD group with one of several LRRK2 and GBA variants 
including rs34637584, rs421016, and rs76763715 have reported them having significantly 
higher incidence and earlier onset of depressive symptoms than the non-carriers (49) 
supplementary information table-2.
APOE: Most of the studies that investigated the effects of APOE ε4 allele on cognition in 
people with PD have documented a weak association between the allele and cognitive 
impairment in PD (8). Significantly more rapid cognitive decline, measured by the Hamilton 
Verbal Learning test (50) and the Mattis Dementia Rating Scale-II (6), has been reported in 
people with PD carrying APOE ε4 allele. However, there are negative studies that failed to 
replicate this association (51,52). A prior meta-analysis of studies that investigated the 
genetic association between APOE ε4 allele and cognitive impairment in PD has reported that 
APOE ε4 allele significantly increases the risk of PDD (OR=1.74; 95%CI 1.36–2.23; 
p=0.0001). However, this meta-analysis has documented significant heterogeneity of relevant 
studies, and the possibility of publication bias (8).
SLC6A4: Three studies have investigated the association between serotonin transporter gene 
(SLC6A4) 5-HTTLPR variant and depressive symptoms in people with PD. Earliest and the 
smallest (N=32) of them reported that people with PD carrying short allele of the 5-HTTLPR 
variant scored significantly higher on depressive symptoms than corresponding non-carriers 
(53). Later, two later relatively larger studies have clarified that people with PD carrying this 
short allele did not differ significantly from non-carriers on their depressive symptoms 
(29,54). Moreover, a recent large genetic association study using multiple population based 
and case control samples regardless of their PD diagnoses has reported that the association 
between SLC6A4 5-HTTLPR variant and depressive symptoms was not statistically 
significant (55).
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Other genetic variants associated with cognitive impairment in PD: Supplementary 
information table-3 provides an overview of the studies that investigated the associations 
between cognitive impairment in PD and various genetic variants. A recent study has 
investigated the associations between 249,336 genetic variants and various cognitive 
functions in 1105 people with PD, and it has reported false discovery rate adjusted 
statistically significant associations of 18 genetic variants with the results of one of the 
cognitive tests. These genetic variants include PARP4 (rs9318600, rs9581094), MDM1 
(rs117673673), ALS2CR11 (rs72939119), FAT3 (rs75081660), RYR1 (rs55876273), IFT140 
(rs146128830), MTCL1 (rs34877994), MOCS3 (rs7269297), RASAL3 (rs56209154), and 
ACSBG2 (rs79266675) (45). Most of these reported genetic associations have not been 
replicated so far, so they need to be interpreted with caution. People with PD carrying at least 
one Met allele of BDNF (rs6265) variant have been found to have significantly more 
cognitive impairment than non-carriers (56). Moreover, MAPT H1/H1 genotype has been 
reported to be an independent predictor of PDD (57). Low activity COMT (Val158Met) 
Met/Met genotype has been associated with cognitive impairment in PD(58), but another 
study failed to verify this association (51). Furthermore, a PICALM variant (rs3851179) has 
been reported to be associated with cognitive impairment in people with PD older than 70 
years (59), and this finding needs further replication. 
Other genetic variants associated with depression in PD: Supplementary information table-
4 summarises the findings of the studies that investigated the associations between various 
genetic variants and depressive symptoms in PD. BDNF (rs6265) variant has been associated 
with depression in people with PD, after accounting for the effects of potential confounders 
such as gender, disease progression, and motor symptoms (p=0.046) (60). TEF TT genotype 
(61), CRY1 CC genotype (61), SLC6A15 (rs1545843)(27), and TPH2 (rs78162420) (27) have 
been associated with depression in people with PD, and these findings have not been 
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replicated so far. Moreover, people with PD carrying SNCA Rep1 (CA)12/12 genotype 
reportedly has a reduced risk of depression (p=0.02) (48). Another study has reported a 
significant association (p=0.003) between a specific CNR1 genotype and reduced risk of 
depression in PD (62).  
Discussion 
For the first time, we systematically reviewed all studies that investigated the 
associations between various genetic variants and cognitive impairment and/or depressive 
symptoms in people with PD. The systematic review found that LRRK2 variant rs34637584 
has been associated with significantly less cognitive impairment in PD, and we confirmed it 
by a meta-analysis. More meta-analyses confirmed that GBA variants rs76763715 (p<0.001) 
and rs421016 (p=0.001) were significantly associated with more cognitive impairment in 
people with PD. Moreover, the systematic review has listed the genetic variants that have 
been associated with depression in PD, including GBA (rs76763715, rs421016, rs387906315 
and rs80356773, BDNF (rs6265) and CRY1 (rs2287161) variants. 
The strengths of this systematic review include its broad inclusion criteria, searching 
multiple databases including grey literature, following PRISMA guidelines, and quality 
assessment using the Q-Genie instrument. Nonetheless, we must acknowledge the limitations 
of excluding the studies that were not published in English, not including gene expression 
and epigenetic studies, and of substantial heterogeneity among the included studies. Most of 
the included studies were small, and they have not reported sample size estimation or power 
analysis, so they were prone to type-II error. Moreover, there were only five longitudinal 
studies, and other studies did not evaluate the longitudinal changes in cognition and mood of 
their participants. Many studies have recruited participants only from specific ethnic groups, 
such as Ashkenazi Jews, and their findings have limited generalisability. Furthermore, there 
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are concerns over the validity of outcome measures like MMSE, employed by these studies, 
for assessing cognition and depressive symptoms in people with PD.
LRRK2 variants have the largest body of evidence in this topic. LRRK2 variant 
rs34637584 may either delay or prevent cognitive decline on its own or because of its 
interactions with other genetic variants in people with PD (14,15,27,30). LRRK2 encodes a 
kinase, and the minor allele of rs34637584 leads to increased expression and activity of 
LRRK2 (63) because of stabilising the kinase activation loop (64). Furthermore, the severity 
of Lewy body pathology correlates with the severity of cognitive impairment in PD (65), and 
LRRK2 related PD can be with or without the presence of Lewy bodies (13). Overexpression 
of LRRK2 leads to enlarged lysosomes, lower endolysosomal pH, impaired autophagy, and 
diminished lysosomal degradation in-vitro (66), and these changes in the morphology and 
function of lysosomes could be reversed by LRRK2 kinase inhibitors in-vitro (66). A 
neuronal cell culture study using mouse embryos that were homozygous for LRRK2 
rs34637584 variant has replicated these findings (67). Despite the progress in the mechanistic 
understanding of LRRK2 overexpression leading to neurodegeneration in PD, the molecular 
mechanisms underlying relative preservation of cognitive functioning in people with PD 
carrying LRRK2 overexpressing variant rs34637584 remain uncertain. 
GBA encodes lysosomal acid glucosylceramidase, and homozygous GBA variants 
cause Gaucher’s disease (GD) that is a lysosomal storage disorder. Minor alleles of GBA 
variants rs76763715, rs421016, rs387906315 and rs80356773 lead to glucosylceramidase 
protein misfolding that in turn may lead to either loss or gain of function (68). 
Glucosylceramidase deficiency leads to autophagy impairment, lysosomal dysfunction, and 
accumulation of α-synuclein oligomers. These α-synuclein oligomers disrupt misfolded 
glucosylceramidase, and set off a vicious cycle leading to neurodegeneration and cognitive 
impairment in people with PD carrying GBA variants (68). Prior studies have reported the 
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associations between these GBA variants and increased presence of cortical Lewy bodies 
(69). Our systematic review and meta-analyses have confirmed the associations of these GBA 
variants with cognitive impairment and depression in people with PD. There is a need for 
further studies investigating the clinical utility and cost-effectiveness of screening for these 
GBA variants for early identification of the non-motor symptoms. GBA variant rs421016 is 
associated with more severe phenotype of PD and GD than rs76763715 variant (70), and 
LRRK2 rs34637584 leads to more benign PD phenotype than other LRRK2 variants (71). 
However, little is known about the differential effects of these variants on cognitive 
impairment and depression in people with PD (43). Non-manifesting LRRK2 rs34637584 
carriers have been reported to have significantly more cognitive impairment than non-
manifesting carriers of GBA variants (72). Hence, further investigation focusing on the 
effects of individual LRRK2 and GBA variants on the non-motor symptoms of PD is 
warranted.
Although there is substantial heterogeneity among the studies that investigated the 
associations between genetic variants and depressive symptoms in PD, it is possible to derive 
important conclusions. The studies differed widely on their participant characteristics, 
assessment of depressive symptoms, threshold for diagnosing depression, and their analyses 
addressing potential confounders. Statistically significant associations between depression in 
PD and BDNF (rs6265), TEF TT genotype (61), CRY1 CC genotype (61), SLC6A15 variant 
rs1545843 (27), and TPH2 variant rs78162420 (27) have been reported. These reported 
genetic associations are only tentative, and they need further replication. Further larger 
studies including structured diagnostic interviews and detailed assessment of confounding 
psychosocial variables are needed for verifying these reported genetic associations. Unlike 
the progressive cognitive decline in PD, depressive symptoms in people with PD are often 
episodic and responsive to treatment with antidepressant medications. However, most of the 
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genetic association studies investigating depression in PD are cross-sectional, and they have 
not added any information on the longitudinal course of depressive symptoms, and their 
response to antidepressant medications in PD. Further longitudinal studies are needed for 
addressing this issue. Moreover, a SNCA genotype (48), and a CNR1 genotype (62) have been 
associated with reduced risk of depression in PD.  There is a need for investigating whether 
these two genetic associations can be replicated. If they can be replicated, investigating 
underlying molecular mechanisms may facilitate identifying novel therapeutic targets.
Non-motor symptoms of PD have devastating consequences to the service users, their 
families, and societies. Early identification, and appropriate multidisciplinary management of 
non-motor symptoms may imp ove the quality of life of people with PD (73). The importance 
of further systematic research investigating the genetics and molecular biology of non-motor 
symptoms of PD cannot be overemphasised. Despite the studies highlighting the association 
between Lewy body pathology and cognitive impairment in PD (65), there is a conspicuous 
gap in the available literature for studies investigating the associations between SNCA variants 
and non-motor symptoms in PD. Moreover, poor replication, and inconsistent findings of 
reported genetic associations can be explained by small sample of size, lack of study power, 
and by the differences in outcome measures. Larger multi-centre international collaborations 
are necessary for conducting future genetic association studies with adequate statistical 
power. Developing a consensus for standardised assessment of non-motor symptoms in PD 
will help larger international collaborations and will enhance the generalisability of the study 
findings. Furthermore, future studies should consider investigating the pharmacogenetic 
associations between the genetic variants and clinical responses to various medications 
treating non-motor symptoms of PD.  
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Figure Legends:
Figure-1: A PRISMA flow-chart illustrating the selection process of the 43 articles obtained 
with reasons for exclusion. 
PD = Parkinson’s Disease, *Cannot obtain full text of grey literature and author(s) could not 
be contacted
Figure-2: The meta-analysis of five studies investigating the association between LRRK2 
variant rs34637584 and cognitive impairment in people with PD
Figure-3: The meta-analyses of studies investigating the associations between cognitive 
impairment in people with PD and GBA variants rs76763715 (Figure-3A), and rs421016 
(Figure-3B).
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Table-1: Studies investigating the effects of LRRK2 variants on cognition in people with PD
Article Sample Size Mean Age (SD) 
years
Mean UPDRS-
III (SD)
variants Outcome Findings
Alcalay  et 
al. (2010) 
(32)
699 (20 rs34637584) 54.9 (7.9) 19.8 (14.7) rs34637584 MMSE MMSE scores did not differ significantly among the study groups.
Belarbi et al. 
(2010) (33)
71 (23 rs34637584) High-education = 
52.14 (7.22) 
Low-education = 
57.88 (5.78) 
n/s rs34637584 MMSE; MDRS Low MMSE scores were significantly more frequent in rs34637584 
carriers than in non-carriers within the low-educational level group 
(p=0.04), but not in the other group.
Shanker et 
al. (2011) 
(36)
42 (21 rs34637584) 58.7 (9.7) 9.5 (5.6) rs34637584 MMSE; HVLT; 
JLO; FAB
Those with rs34637584 minor allele scored significantly higher on JLO 
(p=0.01) and frontal assessment battery (p=0.01). 
Ben Sassi et 
al. (2012) 
(35)
110 (55 rs34637584) 61.9 (11.8) n/s rs34637584 MMSE; MoCA; 
FAB 
Cognitive functions did not differ significantly among PD patients with 
and without rs34637584 variant.
Estanga et 
al. (2014) 
(28)
60 (30 rs33939927) 69.97 (10.64) 18.86 (10.61) rs33939927 Boston Naming 
Test
Carriers performed significantly worse in the Boston Naming test 
(p=0.03)
Wang et al. 
(2014) (31)
1638 (223 LRRK2) 61.61 (10.90) 22.53 (14.17) rs34778348, 
rs33949390 
MMSE; ADAS Cognitive impairment did not differ significantly between carriers and 
non-carriers (p=0.371).
Alcalay et 
al. (2015) 
(14)
236 (116 rs34637584) 66.7 (10.0) 21.4 (12.2)  rs34637584 Stroop Word 
Reading; Stroop 
Interference; 
Category 
Fluency
rs34637584 carriers performed significantly better in stroop word 
reading (p=0.001), stroop interference (p=0.01) and in category fluency 
(p=0.026).
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Somme et 
al. (2015) 
(15)
54 (12 rs34637584, 15 
rs33939927)
rs34637584 = 
66.1 (11.1), 
rs33939927 = 
62.1 (6.5)
rs34637584 = 
29.8 (15.9)
rs33939927 = 
28.5 (8.4)
rs34637584, 
rs33939927
MDRS II; 
RAVLT
LRRK2 carriers showed significantly less cognitive impairment (MDRS: 
131.2 (10.9) vs. 119 (24.0); p=0.02), (RAVLT, immediate recall:  39.2 
(9.5) vs. 27.6 (12.8); p<0.001), (RAVLT, delayed recall: 7.2 (3.7) vs. 4.7 
(4.0); p =0.022).
Srivatsal et 
al. (2015) 
(30)
1355 (24 rs34637584, 
5 rs33939927)
67.9 (9.6) n/s rs34637584,
rs33939927
MMSE; Letter-
Number 
Sequencing Test
LRRK2 carriers were found to exhibit significantly better performance 
on MMSE (p=0.03) and Letter number sequencing test (p=0.005). 
Zheng et al. 
(2015) (37)
90 (45 rs11564148) 60.79 (10.19) 23.34 (9.88) rs11564148 Stroop word 
colour test
Cognitive impairments did not correlate significantly with different 
LRRK2 rs11564148 variants in Chinese people with PD (p=0.051).
Hong et al. 
(2017) (34)
299 (23 rs33949390) 67.7 (7.8) 30.8 (20.7)  rs33949390 MMSE; MoCA rs33949390 was not significantly associated with cognitive impairment 
measured by MMSE (carriers=25.6 (4.4), non-carriers=25.0 (4.0), 
p=0.442).
UPDRS: Unified Parkinson’s Disease Rating Scale; HVLT: Hamilton Verbal Learning Test; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; 
ADAS: MDRS: Mattis Dementia Rating Scale; The Alzheimer’s Disease Assessment Scale – Cognitive; RAVLT: Rey's auditory verbal learning test; JLO: Judgment of Line 
Orientation test; FAB: Frontal assessment battery; n/s: Not specified.
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Table-2: Studies investigating the effects of GBA variants on cognition in people with PD
Article Sample Size Mean Age (SD) 
years
Mean UPDRS-III 
severity (SD)
variants Outcome Findings
Alcalay et al. 
(2010) (32) 
699 (37 GBA) 54.4 (4.9) 23.8 (11.3) rs76763715  
rs421016
MMSE MMSE scores did not differ significantly among the 
study groups.
Brockmann et al. 
(2011) (46)
40 (6 rs76763715, 
14 rs421016)
GBA-PD= 62.75 
(10.4); Sporadic 
PD= 67.60 (9.3)
GBA-PD= 34.75 
(14.1); Sporadic PD= 
27.85 (7.5) 
rs76763715, 
rs421016 
MoCA Cognitive impairment was significantly more 
frequent (45% vs 30%) and more severe (22.53 vs 
26.53 MoCA points) among GBA-PD compared to 
sporadic PD (p=0.02).
Alcalay et al. 
(2012) (12)
71 (24 GBA) 59.0 (6.7) 35.1 (11.5) rs76763715, 
rs421016, 
rs387906315, 
rs80356773 
MMSE, CVLT-
II, BVRT, 
COWAT, 
WMS-R
GBA variant carriers performed significantly worse 
on MMSE (p=0.035), visual memory (p<0.001), 
and visuospatial ability (p=0.025). 
Brockmann et al. 
(2015) (40)
47 62.75 (10.4) 34.75 (14.1) rs76763715, 
rs421016 
MoCA GBA variant carriers developed significantly more 
cognitive decline than non-carriers over three years 
follow-up period (p=0.01)
Malec-
Litwinowicz et 
al. (2014) (42) 
138 (16 GBA) 57.2 (2.8) 36.4 (18.5) rs76763715, 
rs75548401
MMSE GBA rs76763715 carriers were significantly more 
likely to develop dementia (MMSE score<26) 
(p=0.03).
Wang et al. 
(2014) (31) 
1638 (49 GBA) 61.61 (10.90) 22.53 (14.17) rs421016 MMSE; ADAS Cognitive impairment did not differ significantly 
between carriers and non-carriers (p=0.474).
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Zokaei et al. 
(2014) (44)
67 (15 GBA) 61.0 (9.0) n/s rs76763715, 
rs421016 
VSTM GBA-positive people with showed significantly 
worse recall than other study groups (p<0.005)
Davis et al. 
(2016) (41) 
733 (58 GBA) 64.0 (9.0) 31.8 (10.6) GBA coding 
region variants, 
rs2230288
“Detailed 
cognitive 
testing”
A significantly higher proportion of rs2230288 
carriers (p=0.01) and of other GBA variant carriers 
(p=0.04) progressed to mild cognitive impairment 
or dementia.
Mata et al. 
(2016) (43) 
1369 (125 GBA) 57.3 (12.3) 30.4 (12.3) GBA coding 
region variants, 
rs2230288
MoCA, Letter-
Number 
sequencing, trail 
making, JLO
GBA carriers had a higher prevalence of dementia 
(p=9.7×10−6) and lower performance on letter-
number sequencing, trail making, and JLO 
(p=0.0045).
Mata et al. 
(2017) (45)
1105 68.8 (9.2) n/s NeuroX array 
(249,336 
variants)
HVLT-R, 
MoCA, JLO, 
language 
processing and 
executive 
function tests
18 common variants in 13 genomic regions 
exceeded the genome-wide significance threshold 
for one of the cognitive tests. They included GBA 
rs2230288 (PFDR = 2.7 × 10−4) for JLO.
Liu et al. (2017) 
(74)
3200 (308 GBA) n/s n/s n/s MMSE A multivariable cognitive risk score including the 
GBA variants could predict dementia or disabling 
cognitive impairment with an area under curve of 
0.88 (95%CI 0.79–0.94) and negative predictive 
value of 0.92 (95%CI 0.88–0.95).
UPDRS: Unified Parkinson’s Disease Rating Scale; MMSE: Mini-Mental State Examination; CVLT-II: California Verbal Learning Test-II; BVRT: Benton 
Visual Retention Test; COWAT: Controlled Oral Word Association Test; WMS-R: Wechsler Memory Scale–Revised; MoCA: Montreal Cognitive 
Assessment; ADAS: The Alzheimer’s Disease Assessment Scale - Cognitive; VSTM: Experimental visual short-term memory task; JLO: Benton Judgment of 
Line Orientation; HVLT-R: Hamilton Verbal Learning Test-Revised; n/s: Not specified.
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UPDRS: Unified Parkinson’s Disease Rating Scale; BDI-II: Beck’s Depression Inventory II; CES-D: Center for Epidemiologic Studies-Depression; HDRS – 
Hamilton Depression Scale; n/s: Not specified.
Table-3: Studies investigating the effects of GBA variants on depressive symptoms in people with PD
Article Sample Size Mean Age (SD) 
years
Mean UPDRS-III 
severity (SD)
variants Outcome Findings
Brockmann et al. 
(2011) (46)
40 (6  
rs76763715, 14  
rs421016)
GBA-PD= 62.75 
(10.4); Sporadic 
PD= 67.60 (9.3)
GBA-PD= 34.75 
(14.1); Sporadic PD= 
27.85 (7.5) 
rs76763715, 
rs421016
BDI-II GBA-PD people had significantly more 
depressive symptoms (BDI II: 12.05 Vs 
7.10) than people with sporadic PD (p= 
0.03).
Brockmann et al. 
(2015) (40)
47 62.75 (10.4) 34.75 (14.1) rs76763715,  
rs421016 
BDI-II GBA variant carriers did not differ 
significantly on their depressive 
symptoms than non-carriers over three 
years follow-up period.
Swan et al. (2014) 
(47) 
86 (31 GBA) 65.6 (12.5) 16.7 (8.7) rs76763715,  
rs421016, 
rs387906315, 
rs80356773 
 BDI GBA variant carriers had significantly 
higher prevalence of depression (33.3%) 
than non-carriers (13.2%) (p=0.03)
Wang et al. (2014) 
(31) 
1638 (49 GBA) 61.61 (10.90) 22.53 (14.17) rs421016 CES-D GBA variant carriers had significantly 
higher CES-D scores above 16 than other 
study groups (p=0.048).
Dan et al. (2016) 
(48) 
1047 (40 GBA) With depression= 
61.66 (9.98) 
Without 
depression= 62.05 
(10.20) 
With depression = 
30.01 (16.16) Without 
depression = 22.00 
(12.64)
rs421016 HDRS rs421016 was associated with 
significantly increased risk of depression 
(Odds Ratio=2.69, 95%CI 1.31-5.53; 
p=0.007).
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A PRISMA flow-chart illustrating the selection process of the 43 articles obtained with reasons for exclusion. 
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cognitive impairment in people with PD 
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The meta-analyses of studies investigating the associations between cognitive impairment in people with PD 
and GBA variants rs76763715 (Figure-3A), and rs421016 (Figure-3B). 
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Supplementary Information Table 1: Quality assessment of included studies using ‘Q-Genie’ quality assessment tool 
Study Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Score
Burn et al. (2006) (1) 4 4 4 5 4 5 5 5 5 4 5 55
Chahine et al. (2018) (2) 4 5 5 4 5 4 4 6 5 4 5 51
Wang et al. (2016) (3) 4 5 4 5 5 4 4 5 4 5 5 50
Nombela et al. (2014) (4) 5 5 4 5 5 4 5 4 3 4 5 49
Dan et al. (2016) (5) 5 5 3 2 2 4 5 5 4 4 4 47
Williams-Gray et al. (2009) (6) 4 5 4 4 4 3 5 4 4 5 5 47
Zokaei et al. (2014) (7) 5 5 4 5 4 3 4 5 4 4 4 47
Alcalay et al. (2010) (8) 4 4 5 5 5 3 5 4 4 3 4 46
Dissanayaka et al. (2009) (9) 4 4 5 5 4 4 5 4 3 3 4 45
Tröster et al. (2006) (10) 4 6 5 2 4 3 3 5 4 4 4 44
Mata et al. (2017) (11) 5 6 n/a 5 4 3 4 5 3 4 5 44
Barrett et al. (2016) (12) 3 3 4 6 4 3 5 4 4 4 3 43
Alcalay et al. (2015) (13) 3 4 5 2 3 5 5 4 3 4 4 42
Cagni et al. (2017) (14) 4 3 4 5 3 3 5 4 4 3 4 42
Beavan et al. (2015) (15) 4 3 4 3 2 3 4 5 4 3 4 39
Mata et al. (2014) (16) 4 5 n/a 5 5 6 5 5 5 5 5 39
Morley et al. (2012) (17) 3 3 2 3 4 4 5 3 4 4 4 39
Wang et al. (2014) (18) 4 4 n/a 5 4 4 5 3 3 4 3 39
Alcalay et al. (2012) (19) 3 3 4 3 2 4 4 4 4 3 4 38
Mata et al. (2016) (20) 3 3 4 4 3 3 5 3 3 3 4 38
Swan et al. (2014) (21) 3 2 3 4 3 3 4 4 3 4 4 37
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Williams-Gray et al. (2008) (22) 3 3 4 3 2 3 4 4 4 3 4 37
Barrero et al. (2005) (23) 4 4 3 3 3 2 4 3 4 3 3 36
Belarbi et al. (2010) (24) 3 3 4 4 4 2 4 3 3 4 2 36
Davis et al. (2016) (25) 4 3 3 5 4 3 2 3 4 4 3 36
Srivastava et al. (2011) (26) 4 3 2 2 2 2 5 4 4 3 3 36
Gaig et al. (2014) (27) 3 3 3 2 3 4 4 4 3 3 3 35
Shanker et al. (2011) (28) 2 3 4 2 5 4 3 3 3 3 3 35
Da Silva et al. (2017) (29) 3 4 4 3 2 3 2 3 2 4 5 35
Brockmann et al. (2011) (30) 3 3 4 2 3 3 3 3 4 3 3 34
Hua et al. (2012) (31) 4 3 n/a 2 2 3 4 4 5 4 3 34
Zheng et al. (2017) (32) 3 4 4 3 3 2 2 3 4 3 3 34
Altmann et al. (2016) (33) 4 3 n/a 3 2 3 4 3 4 3 4 33
Malec-Litwinowicz et al. (2014) (34) 3 3 3 2 2 3 4 3 3 3 3 32
Menza et al. (1999) (35) 4 4 3 3 2 3 2 3 3 2 3 32
Ben Sassi et al. (2012) (36) 4 4 3 2 2 3 3 4 2 2 3 32
Srivatsal et al. (2015) (37) 3 3 3 2 2 3 3 4 4 2 3 32
Hong et al. (2017) (38) 4 3 4 5 4 3 3 4 4 4 3 31
Somme et al. (2015) (39) 4 2 4 2 2 3 2 3 3 3 3 31
Kasten et al. (2012) (40) 3 2 4 2 2 3 2 4 3 2 3 30
Brockmann et al. (2015) (41) 2 2 3 3 4 2 2 3 2 3 3 29
Zheng et al. (2015) (42) 4 3 n/a 2 3 2 2 4 3 2 3 28
Estanga et al. (2014) (43) 5 3  3 1 1 2 1 3 3 3 2 27
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Supplementary Information Table 2: Genetic variants and associated amino acid changes
Gene Amino acid changes rs number
LRRK2 G2019S rs34637584
G2385R rs34778348
R1441C rs33939927
R1441G rs33939927
S1647T rs11564148
GBA 84GG rs387906315
E326K rs2230288
L444P rs421016
N370S rs76763715
R496H rs80356773
T369M rs75548401
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Supplementary Information Table 3:  Studies investigating the genetic associations between cognitive impairment in people with Parkinson’s 
disease and various genetic variants
Article Sample Size Mean Age 
(SD)
Mean Severity 
of PD (SD)
Variants Outcome Follow 
up 
duration
Findings
Tröster et al. (2006) 
(10) 
208 (20 APOE) 65.6 (8.2) n/s APOE (ε4 allele) MDRS; 
WMS—
Revised; WCST
n/s Carriers and non-carriers differed in their cognitive 
performance (BNT: carriers = 49.7 (11.7), non-carriers 
= 52.0 (6.4), p=0.001,  WCST: carriers = 3.4 (2.4),  
non-carriers = 3.1 (2.6), p=0.001), however this was 
not significant after controlling for age.
Williams-Gray et 
al. (2008) (22) 
29 Val = 64.8 
(10.4), Met = 
64.0 (9.4) 
n/s COMT (rs6265) Modified 
CANTAB 
ID/ED task
n/s People with high activity COMT genotypes (val/val) 
adopted an approach of preferentially shifting 
attention within dimensions rather than between. 
Those with low activity genotypes (met/met) did not, 
which suggests an inability to form an attentional ‘set’. 
Williams-Gray et 
al. (2009) (6) 
528 (107 from 
incident cohort)
62.5 (11.8) n/s APOE (ε4 and ε2 
allele)
MMSE Incident 
cohort = 
5 years 
(0.7)
A case-control study comparing PD patients and 
healthy controls found no significant difference 
between the two groups in relation genotype 
distribution of APOE. No significant difference in  
“change in MMSE per year” was found (Mann-
Whitney U test, p=0.27).
Morley et al. (2012) 
(17) 
269 71.0 (7.4) UPDRS-III
23.0 (11.0)
APOE (ε4 allele) MDRS version 
II
1 year The ε4 allele of APOE was associated with more rapid 
decline (loss of 2.9 more points/year, p<0.001) in total 
score and an increased risk of a ≥10 points drop during 
the follow-up period (HR=2.8, p=0.003). 
Mata et al. (2014) 
(16) 
1079 68.8 (9.1) n/s APOE (ε4 allele), 
MAPT variants, 
SNCA (rs356219)
HVLT-R; 
Letter-Number 
Sequencing Test 
and Trail 
Making Test; 
MoCA
n/s The APOE ε4 allele was associated with lower 
performance on the HVLT-R total recall (p=6.7 × 
10−6; corrected pc=6.0 × 10
−5), delayed recall (p = 
.001; pc=.009), and recognition discrimination Index 
(p=.004; pc=.04).
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Nombela et al. 
(2014) (4) 
235 (49 PD from 
cohort 1 (C1) and 
102 from cohort 2 
(C2) and 49 
controls from C1 
and 35 from C2)
PD C1 = 65.36 
(7.9), PD C2 = 
64.81 (11.1), 
Controls C1 = 
63.83 (5.8), 
Controls C2 = 
66.23 (8.4)
UPDRS-III 
PD C1 = 29.28 
(11.02 )
PD C2 = 25.36 
(10.7)
COMT  and MAPT 
variants, and APOE 
(ε4 allele)
Tower of 
London task; 
Spatial 
Rotations Task; 
MMSE
n/s A repeated measures ANCOVA revealed no effect of 
disease or interaction between disease and site on 
accuracy in the Tower of London Task. For the Spatial 
Rotations Task, there was a trend towards a disease 
effect [F(1,207) = 3.319, p<0.07, lower score in 
patients] but no significant interaction. 
Altmann et al. 
(2016) (33) 
175 68.8. (9.3) n/s BDNF (rs6265) MMSE n/s Carriers of at least one BDNF Met allele presented 
with more cognitive impairment (p=0.005). 
Barrett et al. (2016) 
(12) 
1468 (471 from 
the GenePD 
cohort and 997 for 
the NGRC cohort)
GenePD = 62.0 
(10.5)
NGRC = 58.5 
(11.9) 
n/s Variants in BIN1, 
CLU, ABCA7, 
CR1, PICALM, 
MS4A6A, CD33, 
MS4A4E, CD2AP
 
MMSE n/s PICALM rs3851179 was associated with cognitive 
impairment (MMSE < 24) in PD subjects>70 years old 
but not in PD subjects≤70 years old.
Wang et al. (2016) 
(3) 
296 62.60 (9.40) UPDRS-III
22.62 (13.83)
SNCA 
(rs11931074, 
rs894278)
MAPT (rs242557, 
rs3744456) 
MMSE 4 years Increased severity of cognitive impairment was 
associated with MAPT H1c haplotype ( p=0.05) with 
none of the risk alleles chosen associated with survival 
to the cognitive cutoff (p>0.05). 
PD: Parkinson’s disease; UPDRS: Unified Parkinson’s Disease Rating Scale; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; HVLT-R: 
Hamilton Verbal Learning Test–Revised; WMS: Wechsler Memory Scale; WCST: Wisconsin Card Sorting Test; MDRS: Mattis Dementia Rating Scale; CANTAB ID/ED: 
Cambridge Neuropsychological Test Automated Battery intra-dimensional/ extra-dimensional; BNT: Boston Naming Test; NGRC: Genome-Wide Association Study of 
Parkinson Disease: Genes and Environment 
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Supplementary Information Table 4: Studies investigating the genetic associations between depressive symptoms in people with Parkinson’s 
disease and various genetic variants
Article Sample Size Mean Age 
(SD)
Mean 
Severity of 
PD (SD)
Variants Outcome Findings
Menza et al. (1999) 
(35) 
32 67.0 n/s 5-HTTLPR 
(SLC6A4)
 HDRS Those with the short allele of the serotonin transporter promoter 
scored significantly higher on depression (p<0.004).
Barrero et al. 
(2005) (23) 
89 Men = 67.2 
(11); Women 
= 73.4 (6.3) 
UPDRS
56.4 (30.5)
CNR1 variants  HDRS The presence of two long alleles in the CNR1 gene was associated 
with a reduced prevalence of depression (p=0.003).
Burn et al. (2006) 
(1) 
190 (108 5-HTTLPR) 71.1 (8.2) n/s 5-HTTLPR 
(SLC6A4)
MADRS; GDS-
15
No association between 5-HTTLPR genotype or the presence of the 
S allele and the risk of depression measured by MADRS or GDS-
15.
Dissanayaka et al. 
(2009) (9) 
190 (95 with 
depression and 95 
without depression)
With 
depression = 
n/s, without 
depression = 
69.9 (8.0)
n/s SLC6A3 and 
SLC6A4 variants
 GDS-15 There were no significant differences in haplotype frequencies 
between depressed people and not depressed groups; SLC6A4 
(p=0.69) and SLC6A3 (p=0.41).
Srivastava et al. 
(2011) (26)
88 51.8 (9.7) UPDRS-III
19.75 (7.25)
PRKN variants PHQ-MD; 
BDI-II
Only compound heterozygotes had a significantly high BDI-II score 
and BDI-II total depression score (b=8.4; 95% CI 2.4-11.3) 
compared to those without PRKN variants.
Hua et al. (2012) 
(31) 
408 65.3 (10.2) UPDRS-III = 
25.7 (15.1)
Cry1 (rs2287161), 
Cry2 (rs10838524) 
and Tef (rs738499) 
variants. 
 HDRS Higher HDRS scores were found in the TT genotype group in Tef 
rs738499 (p<0.01) and the CC genotype group in Cry1 rs2287161 
(p<0.01). There was no difference in HDRS scores between the 
CRY2 AA genotype and AG genotype (rs10838524).
Kasten et al. (2012) 
(40) 
42 (2 SNCA, 8 
PRKN, 9 PINK1 and 
4 LRRK2)
Carriers = 44 
(13) (MMC), 
UPDRS-III
16.7 (13.9) 
(MMC)
Variants in SNCA, 
Parkin, PINK1, 
LRRK2
BDI Frequency of depression was increased in all PD groups, 
particularly the MMC (0.44) and EOPD (0.31) groups. However the 
treated disease controls had the highest proportion of at least 
moderate depressive symptoms at 0.63. 
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Cagni et al. (2017) 
(14) 
200 (104 BDNF) 64.32 (11.71) UPDRS-III
Carriers 
(G/G) = 
21.72 (10.8)
Carriers = 
(A/G +A/A) 
= 21.07 
(8.07)
BDNF (rs6265)  BDI People with PD presented more prevalent and severe depression 
symptoms, measured by BDI (7.18 (7.80) versus 16.22 (9.52), 
p=0.0001), when compared with controls. 
Zheng et al. (2017) 
(32) 
330 (125 depression 
and 205 without 
depression)
With 
depression = 
62.3 (10.3), 
Without = 
61.8 (11.6)
n/s SNCA variants  HDRS Significant differences between the two groups in minor allele 
frequency of SLC6A15 rs1545843 and in frequencies of genotypes 
and minor alleles of rs78162420 in TPH2. 
UPDRS: Unified Parkinson’s Disease Rating Scale; PHQ-MD: The Patient Health Questionnaire of the Primary Care Evaluation of Mental Disorders; HDRS: Hamilton 
Depression Rating Scale; BDI: Beck’s Depression Inventory; MADRS Montgomery– Asberg  rating scale; GDS-15: Geriatric Depression Scale – 15 items; MMC: Early-Onset 
Manifesting Carriers; EOPD: Early-Onset Parkinson’s Disease
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